Triple vaccine for salmonella, riemerella anatipestifer and escherichia coli

Abstract

The invention belongs to the technical field of veterinary biological products, and particularly relates to a triple vaccine for salmonella, riemerella anatipestifer and escherichia coli. Antigens adopted are an inactivated salmonella typhimurium S01 strain, a riemerella anatipestifer R01 strain and an escherichia coli E01 strain. The three strains used by the vaccine disclosed by the invention are high in toxicity and immunogenicity and have relatively good cross protectiveness. The vaccine prepared by the invention is good in safety, and any local and systemic adverse reactions caused by the vaccine are avoided. Various indexes are stable and effective through analysis of characters, and data in the safety test and efficacy test in a storage life test; and results of the efficacy test prove that the triple inactivated vaccine can generate a good antibody and can generate relatively good toxicity protection efficiency.

Description

Technical field:

[0001] The invention belongs to the technical field of veterinary biological products, in particular to a triple vaccine against Salmonella, Riemerella anatipestifer and Escherichia coli. Background technique:

[0002] Salmonella typhimurium is an important zoonotic pathogen with a wide range of hosts and can cause a variety of acute or chronic infectious diseases in humans and animals. Among them, Salmonella typhimurium of animal origin poses a serious threat to livestock breeding and human health. public health significance. The use of antibacterial drugs is an important measure to treat Salmonella infection, but due to the abuse and indiscriminate use of antibacterial drugs by humans, severe bacterial resistance has been caused. Previous data show that 90% of antibiotics are used in food animals every year in the world. Animals have become an important storage host for drug-resistant bacteria, and drug-resistant bacteria and drug-resistant gene elements ...

Images